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Like other scientists, immunologists use two types of approaches
to research: one reduces the problem to its parts; the other studies
the emergent phenomenon produced by the parts. Scientists that
reduce the problem to its parts are sometimes called reductionists.
The conclusions of reductionist experiments are often applied to
the greater whole, when in actuality they may only apply to that
particular experimental set. We, reductionists, are the ones who
think our immune behavior exists solely because of genes, the
presence of TGFβ, the presence of inflammatory cytokines, and
appearance of a receptor. We tend to interpret the outcome in the
colors of our interests (ergo “to a hammer, everything is a nail”).
We measure parts and from the parts, we draw parallels to far-
removed outcomes in terms of health and disease. More often
than not, however, the results from the study of the parts do not
predict the whole, and often the whole becomes greater than the
sum of its parts. For example, a toll-like receptor does one thing
when there is a bacterial invasion but the same toll-like receptor
may lead to a different outcome when activated by danger signals
during injury.
The approach that is perhaps more applicable to biology, and
more specifically, to immunology, is the chaos theory. The chaos
theory deals with the multiple layers of conditions and unexpected
turns and restarts that can effect the outcome. It is applica-
ble to studies of dynamic systems like the weather, and in our
case, dynamic biological/immunological systems. The chaos the-
ory points out that small differences in initial conditions make it
impossible to predict the outcome. Thus, the behavior of the parts
does not make the outcome predictable.
Our point? Immune privilege is broadly understood as the abil-
ity of the tissue to actively regulate and direct immune responses
that take place in its “territory.” The articles in this Research Topic
in Frontiers in Immunology, “Good news–bad news”, support the
idea that to understand how immune privilege works, one has to
understand the dynamics of the different tissues in terms of initi-
ation, expression, regulation, and behavior, before one can begin
to predict an outcome.
This Research Topic contains a number of papers that deal with
immune privilege in the eye: a review that explores the relationship
of immune privilege to ocular disease (1); a contribution on local
regulation of immune CD8+ T cells in the eye (2); a review dis-
cussing the intriguing parallels between the mechanisms of ocular
immune privilege and uveal melanoma (3); a thoughtful contri-
bution on how CD8+ Treg cells might enable ocular tumor growth
(4); a review proposing that (paradoxically) immune privilege
emerges as an enabler of immune cells that heal, as well as of
regulator immune cells that promote tissue damage (5).
While the eye is considered the prototypic immune privileged
tissue, it is not the only one. We therefore shift to reviews of
immune privilege and its mechanisms in other tissues and organs,
underscoring the universality of the phenomenon: the reproduc-
tive tract (6), the testis (7), tumor environment (8), and finally
chronic inflammatory diseases (9). While the eye, testes, repro-
ductive tract, tumors, and chronic immune diseases all seem to
share some “immune privileged” mechanisms, each has developed
unique features of its own. Recent reports have repeatedly shown
that immune regulation is “tailored” to the individual tissue in
which it is taking place.
Each immune privileged tissue has a unique function. The eye
must protect the light path and signals that stimulate the retina,
and photoreceptors to preserve vision. The testis has to protect the
sperm as they proceed to the epididymis where they mature. The
maternal reproductive tract has to protect its eggs both before and
after fertilization and thus has developed specialized mechanisms
to modify the body’s response to foreign antigens. These unique
challenges require different solutions and lead to unique immune
privilege mechanisms. However, although microenvironment and
the stromal cells that carry out the particular function may vary
between tissues, and consequently the mechanisms that promote
regulation may be unique to that cell or tissue, the goal is the same:
limit collateral damage to preserve tissue integrity and maintain
homeostasis to the extent possible, without compromising host
defense.
Many of the studies in the tissues other than the eye reveal areas
of investigations that have not been well studied in the eye. IDO
exerts profound effects on immune and tissue cells that suppress
pro-inflammatory and immune stimulatory responses to a vari-
ety of insults. While the eye does not have frequent exposure to
foreign antigens, its many layers of immune regulation appears
to allow unmatched cornea grafts long-term survival without sys-
temic immunosuppression. It is clear that we do not know all the
immune privilege paradigms, but by understanding the emergent
phenomena that are produced by the parts of immune privilege
that is used by other tissues, may help to understand the concept
of immune privilege as a whole. The needs of the tissue, its envi-
ronment, and consequently the mechanisms used by each tissue
to immunoregulate may vary. But yet, many of the basic concepts
may be shared. Thus, out of the parts, emerges a whole that is
greater than the sum of the parts.
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We hope this Research Topic has successfully outlined the many
layers involved in immune privilege, established that they vary
with each tissue and clarified that the outcome cannot always be
predicted. Because clinical expectations of medical research often
hurry scientific discoveries prematurely to therapeutic applica-
tions, the scientists who break new ground should also use caution.
Caution, that premature application of the basic science good news
without sufficient understanding and application of the chaos
theory, may lead to bad news.
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